The Growing Burden Of Chronic And Infectious Diseases Fueling The Market Due To Increasing Therapeutic Demand Is Supporting Development Across The mRNA Therapeutics CDMO Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The mRNA Therapeutics CDMO Market?

The mrna therapeutics cdmo market has demonstrated rapid expansion in recent years. Forecasts suggest it will grow from $4.74 billion in 2025 to $5.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. This market’s historical growth can be ascribed to factors such as the constrained availability of specialized mrna cdmo services, a reliance on in-house pharmaceutical manufacturing, an escalation in infectious disease outbreaks, the implementation of early-stage analytical testing, and an increase in academic and research collaborations.

The mrna therapeutics cdmo market size is projected for substantial expansion in the coming years. It is anticipated to reach $8.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This projected growth can be attributed to several factors, including increased investment in mrna therapeutics pipelines, progress in plasmid dna and mrna synthesis technologies, the expansion of cancer immunotherapy and protein replacement therapies, a heightened need for fill-finish services, and an increase in collaborations between biotechnology firms and cdmos. Key trends anticipated during this period encompass a growing demand for outsourced mrna development and production, a stronger emphasis on lipid nanoparticle (lnp) formulation technologies, the broadening of viral vaccine and cancer immunotherapy pipelines, stricter regulatory compliance and quality assurance protocols, and the wider uptake of analytical and bioanalytical laboratory services.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25841&type=smp

Which Drivers Are Advancing The mRNA Therapeutics CDMO Market Growth?

The expanding impact of chronic and infectious diseases is anticipated to drive forward the development of the mRNA therapeutics CDMO market. These conditions encompass persistent health issues such as diabetes, cardiovascular disorders, and asthma, alongside illnesses resulting from disease-causing microbes like viruses, bacteria, and parasites, capable of transmission between individuals. The rise in chronic and infectious diseases is linked to an aging global populace, which demonstrates increased vulnerability to both enduring health problems and infections. The mRNA therapeutics CDMO sector assists in tackling chronic and infectious diseases by offering comprehensive development and manufacturing solutions, thereby speeding up the provision of specific, individualized mRNA treatments to patients. For example, the World Health Organization, a Switzerland-based international public health organization, reported in October 2024 that about 8.2 million individuals received a new tuberculosis diagnosis in 2023, an increase from roughly 7.5 million in 2022, which underscores the increasing global prevalence of infectious diseases. Consequently, the expanding challenge posed by chronic and infectious diseases serves as a key impetus for the expansion of the mRNA therapeutics CDMO market.

What Key Segment Areas Are Included In The mRNA Therapeutics CDMO Market Assessment?

The mrna therapeutics cdmo market covered in this report is segmented –

1) By Type Of Service: Development Services, Manufacturing Services, Laboratory Services

2) By Indication: Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases

3) By Application: Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies

4) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations

Subsegments:

1) By Development Services: Process Development, Analytical Method Development, Formulation Development, Regulatory Support

2) By Manufacturing Services: Plasmid DNA Manufacturing, mRNA Synthesis, Lipid Nanoparticle (LNP) Formulation, Fill-Finish Services

3) By Laboratory Services: Quality Control Testing, Stability Testing, Bioanalytical Testing, Preclinical Testing

Which Trends Are Guiding The Development Of The mRNA Therapeutics CDMO Market?

Major companies operating in the mRNA therapeutics CDMO market are concentrating on creating cutting-edge solutions, such as in situ nanomedicine vaccines, to boost the efficacy and accuracy of mRNA-based vaccines through focused immune activation. An in situ nanomedicine vaccine represents a subsequent generation mRNA-based therapeutic designed to produce nanomedicines directly within a patient’s system, facilitating targeted delivery and bespoke immune activation via engineered transgene expression. For example, in January 2025, Esphera SynBio Inc., a biotechnology firm based in Canada, initiated a new project backed by the CQDM Quantum Leap program. This initiative seeks to improve first-generation lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines by integrating proprietary transgene designs that stimulate the in vivo creation of immunostimulatory nanomedicines. This methodology allows for exact antigen delivery and customized immune responses, positioning the technology as a potential significant advance in vaccine innovation.

Which Key Players Are Active In The mRNA Therapeutics CDMO Market?

Major companies operating in the mrna therapeutics cdmo market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG.

Access The Complete mRNA Therapeutics CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-cdmo-global-market-report

Which Regional Market Leads The mRNA Therapeutics CDMO Market?

North America was the largest region in the mRNA therapeutics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access mRNA Therapeutics CDMO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25841&type=smp

Browse Through More Reports Similar to the Global mRNA Therapeutics CDMO Market 2026, By The Business Research Company

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Mrna Cancer Vaccines And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795